Invivyd, Inc. (IVVD)

NASDAQ: IVVD · IEX Real-Time Price · USD
4.360
+0.020 (0.46%)
Feb 27, 2024, 10:35 AM EST - Market open
0.46%
Market Cap 513.41M
Revenue (ttm) n/a
Net Income (ttm) -169.56M
Shares Out 118.85M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,511
Open 4.350
Previous Close 4.340
Day's Range 4.350 - 4.403
52-Week Range 0.980 - 5.195
Beta 0.74
Analysts Hold
Price Target 6.67 (+52.98%)
Earnings Date Mar 21, 2024

About IVVD

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for t... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 6, 2021
Employees 84
Stock Exchange NASDAQ
Ticker Symbol IVVD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for IVVD stock is "Hold." The 12-month stock price forecast is $6.67, which is an increase of 52.98% from the latest price.

Price Target
$6.67
(52.98% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announc...

21 days ago - GlobeNewsWire

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

VYD222 produced high serum virus neutralizing antibody titer levels in immunocompromised participants Data supportive of an immunobridging approach to the EVADE study of adintrevimab Overall favorable...

2 months ago - GlobeNewsWire

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

WALTHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) --  Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious disease...

3 months ago - GlobeNewsWire

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases...

4 months ago - GlobeNewsWire

Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases...

4 months ago - GlobeNewsWire

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Initial primary endpoint data anticipated in late 2023 or early Q1 2024 Initial primary endpoint data anticipated in late 2023 or early Q1 2024

6 months ago - GlobeNewsWire

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases,...

7 months ago - GlobeNewsWire

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases...

7 months ago - GlobeNewsWire

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases...

7 months ago - GlobeNewsWire

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

WALTHAM, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases...

8 months ago - GlobeNewsWire

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

WALTHAM, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases...

8 months ago - GlobeNewsWire

Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

WALTHAM, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases...

8 months ago - GlobeNewsWire

Invivyd to Participate at the Jefferies Healthcare Conference

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases...

9 months ago - GlobeNewsWire

INVIVYD ALERT: Bragar Eagel & Squire, P.C. is Investigating Invivyd, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Invivyd, Inc. (NASDAQ: IVVD) on behalf of lo...

9 months ago - Business Wire

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from COVID-19

10 months ago - GlobeNewsWire

Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, ...

10 months ago - GlobeNewsWire

Invivyd to Participate at H.C. Wainwright's BioConnect Investor Conference

WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases...

10 months ago - GlobeNewsWire

Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update

WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious disease...

11 months ago - GlobeNewsWire

Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer

WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious disease...

11 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGI

NEW YORK , April 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Invivyd, Inc. (f/k/a Adagio Therapeutics, Inc.) ("Adagio" or the "Company") (NASDAQ: IVVD; ADGI...

11 months ago - PRNewsWire

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Invivyd Investors of a Lead Plaintiff Deadline of April 3, 2023

NEW YORK , April 3, 2023 /PRNewswire/ -- Attention Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd") (NASDAQ: IVVD) shareholders: The Law Offices of Vincent Wong announce that a class action l...

11 months ago - PRNewsWire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 3, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors...

11 months ago - Business Wire

IVVD Investors Have Opportunity to Lead Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Securities Fraud Lawsuit

LOS ANGELES , March 31, 2023 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit ag...

11 months ago - PRNewsWire

IVVD SHAREHOLDER ALERT: Jakubowitz Law Reminds Invivyd Shareholders of a Lead Plaintiff Deadline of April 3, 2023

NEW YORK , March 31, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc....

11 months ago - PRNewsWire

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio Thera...

11 months ago - Accesswire